)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
LAVA Therapeutics (LVTX) investor relations material
LAVA Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Entered into a share purchase agreement with XOMA for acquisition via tender offer at $1.16–$1.24 per share plus contingent value rights, subject to customary conditions and potential adjustments based on net cash at closing.
Acquisition expected to close in Q4 2025, pending shareholder approval and other conditions.
Discontinued Phase 1 clinical trial of LAVA-1266 and initiated wind-down; previously halted LAVA-1207 program after not meeting internal benchmarks.
Implemented a restructuring plan, reducing workforce by approximately 68% and terminating lease arrangements to extend capital resources.
Current pipeline consists of two partnered programs: JNJ-89853413 with Johnson & Johnson and PF-08046052 with Pfizer, both advancing through collaborations.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $56.2 million as of June 30, 2025, down from $76.6 million at year-end 2024.
Net loss for Q2 2025 was $8.6 million ($0.32/share), compared to $8.3 million ($0.31/share) in Q2 2024; net loss for H1 2025 was $12.1 million ($0.45/share), up from $8.9 million ($0.33/share) in H1 2024.
No revenue recognized in Q2 or H1 2025; $7.0 million revenue recognized in H1 2024 from a Pfizer milestone.
R&D expenses decreased to $4.7 million in Q2 2025 from $6.0 million in Q2 2024; G&A expenses fell to $2.6 million from $3.4 million.
Recognized a $5.2 million gain on extinguishment of borrowings in Q1 2025 due to forgiveness of the RVO Innovation Credit.
Outlook and guidance
Cash and investments expected to fund operations for at least 12 months from the report date, with further expense reductions anticipated as strategic alternatives are pursued.
Acquisition by XOMA anticipated to maximize shareholder value, with closing targeted for Q4 2025.
Contingent value right offers potential future payments based on partnered and unpartnered program outcomes.
Future capital requirements may increase if development activities resume or if strategic transactions are not completed.
No guidance provided on future revenue due to the absence of commercial product sales and reliance on milestone payments.
What are the key terms of the XOMA acquisition?
Explain the reasons for discontinuing LAVA-1266.
What is the status of J&J partnered program?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next LAVA Therapeutics earnings date
Q3 20259 Dec, 2025
Next LAVA Therapeutics earnings date
Q3 20259 Dec, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
LAVA Therapeutics N.V. is a biotechnology company focused on developing bispecific gamma-delta T cell engagers (TCEs) for cancer treatment. The company’s proprietary Gammabody platform is designed to activate the immune system by targeting gamma-delta T cells to recognize and destroy tumor cells. LAVA Therapeutics is advancing a pipeline of investigational therapies for hematologic and solid tumors through clinical research and industry collaborations. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage